Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Siobhan Calafiore, Senior Journalist at the limbic, shared a post on LinkedIn about a recent article she authored, published in The Limbic:
“This week I reported on the landmark COBRRA trial addressing one of the common clinical dilemmas for haematologists treating community-acquired blood clots, ‘which anticoagulant do I give my patient?’
For years, clinical guidelines have been unable to preference one DOAC over the other due to a complete lack of head-to-head trials.
The latest findings suggest while both DOACs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, more than halving the risk of bleeding.
Australia had a big role to play in this practice-changing study and I was lucky enough to chat to Australia’s lead investigator Vivien Chen about the practical difference these findings will make in everyday practice around the world. ”
Title: Landmark VTE trial backs apixaban over rivaroxaban
Authors: Siobhan Calafiore
Read the Full Article on The Limbic
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC